| scholarly article | Q13442814 |
| P50 | author | Ireneusz Majsterek | Q87777341 |
| Tomasz Skórski | Q90339764 | ||
| Janusz Błasiak | Q42413439 | ||
| Grażyna Hoser | Q49499674 | ||
| Agnieszka Bronisz | Q64496642 | ||
| P2093 | author name string | Richard Fishel | |
| Artur Slupianek | |||
| Maciej Malecki | |||
| P2860 | cites work | XRCC3 promotes homology-directed repair of DNA damage in mammalian cells | Q24597771 |
| Checkpoint genes required to delay cell division in response to nocodazole respond to impaired kinetochore function in the yeast Saccharomyces cerevisiae | Q24651015 | ||
| DNA repair and recombination factor Rad51 is over-expressed in human pancreatic adenocarcinoma | Q28138134 | ||
| Caffeine abolishes the mammalian G(2)/M DNA damage checkpoint by inhibiting ataxia-telangiectasia-mutated kinase activity | Q28140338 | ||
| Fetal anemia and apoptosis of red cell progenitors in Stat5a-/-5b-/- mice: a direct role for Stat5 in Bcl-X(L) induction | Q28140805 | ||
| 14-3-3Sigma is required to prevent mitotic catastrophe after DNA damage | Q28145962 | ||
| Oncogenic kinase signalling | Q28189493 | ||
| DNA double-strand breaks: signaling, repair and the cancer connection | Q28204231 | ||
| Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia | Q28250886 | ||
| A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia | Q28253771 | ||
| Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells | Q28277030 | ||
| Alternative splicing of RNAs transcribed from the human abl gene and from the bcr-abl fused gene | Q28287743 | ||
| Phosphatidylinositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells | Q28292965 | ||
| Chlorambucil induction of HsRad51 in B-cell chronic lymphocytic leukemia | Q28372141 | ||
| A simple technique for quantitation of low levels of DNA damage in individual cells | Q29014320 | ||
| BCL-2 family members and the mitochondria in apoptosis | Q29614427 | ||
| Rad51-deficient vertebrate cells accumulate chromosomal breaks prior to cell death | Q29614845 | ||
| A mutation in mouse rad51 results in an early embryonic lethal that is suppressed by a mutation in p53 | Q29618277 | ||
| Targeted disruption of the Rad51 gene leads to lethality in embryonic mice | Q29618278 | ||
| Signal transducer and activator of transcription (STAT)5 activation by BCR/ABL is dependent on intact Src homology (SH)3 and SH2 domains of BCR/ABL and is required for leukemogenesis | Q30175784 | ||
| Entry into mitosis in vertebrate somatic cells is guarded by a chromosome damage checkpoint that reverses the cell cycle when triggered during early but not late prophase | Q32030852 | ||
| Signaling pathways activated by oncogenic forms of Abl tyrosine kinase | Q33663180 | ||
| DNA damage-induced cell cycle checkpoints and DNA strand break repair in development and tumorigenesis | Q33814324 | ||
| RecA-mediated strand exchange traverses substitutional heterologies more easily than deletions or insertions | Q33939557 | ||
| Sister chromatid exchanges are mediated by homologous recombination in vertebrate cells | Q33958829 | ||
| Waiting for anaphase: Mad2 and the spindle assembly checkpoint | Q34132901 | ||
| Homologous recombination as a mechanism of carcinogenesis | Q34183753 | ||
| Cellular responses to DNA damage | Q34192725 | ||
| Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway. | Q34250223 | ||
| Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation | Q34340175 | ||
| Signal transduction and transforming properties of the TEL-TRKC fusions associated with t(12;15)(p13;q25) in congenital fibrosarcoma and acute myelogenous leukemia | Q34486039 | ||
| Overexpression of Rad51 protein stimulates homologous recombination and increases resistance of mammalian cells to ionizing radiation | Q34669076 | ||
| Cooperative effects of genes controlling the G(2)/M checkpoint | Q35197422 | ||
| Interleukin 3 protects murine bone marrow cells from apoptosis induced by DNA damaging agents | Q36231901 | ||
| Microtubule dynamics at the G2/M transition: abrupt breakdown of cytoplasmic microtubules at nuclear envelope breakdown and implications for spindle morphogenesis | Q36237507 | ||
| Negative regulation of p120GAP GTPase promoting activity by p210bcr/abl: implication for RAS-dependent Philadelphia chromosome positive cell growth | Q36363202 | ||
| Leukemia treatment in severe combined immunodeficiency mice by antisense oligodeoxynucleotides targeting cooperating oncogenes | Q36365540 | ||
| Inactivation of the cyclin-dependent kinase Cdc28 abrogates cell cycle arrest induced by DNA damage and disassembly of mitotic spindles in Saccharomyces cerevisiae | Q36568230 | ||
| Elevated recombination in immortal human cells is mediated by HsRAD51 recombinase | Q36574017 | ||
| Blastic transformation of p53-deficient bone marrow cells by p210bcr/abl tyrosine kinase. | Q36688711 | ||
| Molecular genetic advances in chronic myelogenous leukemia | Q37781883 | ||
| Ribozyme minigene-mediated RAD51 down-regulation increases radiosensitivity of human prostate cancer cells | Q38302961 | ||
| The tyrosine kinase inhibitor CGP 57148 (ST1 571) induces apoptosis in BCR-ABL-positive cells by down-regulating BCL-X | Q73803450 | ||
| Bcl-xL inhibits cytochrome c release but not mitochondrial depolarization during the activation of multiple death pathways by tumor necrosis factor-alpha | Q74061407 | ||
| Bcr-Abl exerts its antiapoptotic effect against diverse apoptotic stimuli through blockage of mitochondrial release of cytochrome C and activation of caspase-3 | Q74213469 | ||
| Microtubule disassembly delays the G2-M transition in vertebrates | Q74340087 | ||
| BCR-ABL delays apoptosis upstream of procaspase-3 activation | Q74357370 | ||
| Cooperative and redundant effects of STAT5 and Ras signaling in BCR/ABL transformed hematopoietic cells | Q74604694 | ||
| Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow | Q77531813 | ||
| Inhibition of pp60c-Src reduces Bcl-XL expression and reverses the transformed phenotype of cells overexpressing EGF and HER-2 receptors | Q78192920 | ||
| In vitro and in vivo potentiation of radiosensitivity of malignant gliomas by antisense inhibition of the RAD51 gene | Q38338075 | ||
| Bcl-2-independent Bcr-Abl-mediated resistance to apoptosis: protection is correlated with up regulation of Bcl-xL. | Q38338829 | ||
| Oligomerization of the ABL tyrosine kinase by the Ets protein TEL in human leukemia | Q38354873 | ||
| A novel role for the Bcl-2 protein family: specific suppression of the RAD51 recombination pathway | Q39644466 | ||
| Molecular mechanisms of drug resistance in tumours | Q40613086 | ||
| Modelling the process of drug resistance | Q40625830 | ||
| BCR/ABL regulates mammalian RecA homologs, resulting in drug resistance | Q40771883 | ||
| Genetic analysis of the DNA-dependent protein kinase reveals an inhibitory role of Ku in late S-G2 phase DNA double-strand break repair | Q40778006 | ||
| DNA double-strand breaks associated with replication forks are predominantly repaired by homologous recombination involving an exchange mechanism in mammalian cells | Q40814143 | ||
| Role of phosphatidylinositol 3-kinase-Akt pathway in nucleophosmin/anaplastic lymphoma kinase-mediated lymphomagenesis | Q40815965 | ||
| BCR/ABL regulates expression of the cyclin-dependent kinase inhibitor p27Kip1 through the phosphatidylinositol 3-Kinase/AKT pathway | Q40852113 | ||
| Versatility of BCR/ABL-expressing leukemic cells in circumventing proapoptotic BAD effects. | Q40869433 | ||
| STAT5 activation contributes to growth and viability in Bcr/Abl-transformed cells. | Q40895248 | ||
| Homologous recombination and the roles of double-strand breaks | Q40930013 | ||
| A mitotic spindle requirement for DNA damage-induced apoptosis in Chinese hamster ovary cells | Q40949232 | ||
| Regulation of Bcl-2 gene expression by BCR-ABL is mediated by Ras. | Q41120068 | ||
| ts BCR-ABL kinase activation confers increased resistance to genotoxic damage via cell cycle block | Q41150524 | ||
| Role of oncogenes in resistance and killing by cancer therapeutic agents. | Q41414802 | ||
| Activation of hematopoietic growth factor signal transduction pathways by the human oncogene BCR/ABL. | Q41489968 | ||
| Selection for genome instability by DNA damage in human cells: unstable microsatellites and their consequences for tumourigenesis | Q41597208 | ||
| Bcl-2 family proteins: regulators of apoptosis and chemoresistance in hematologic malignancies. | Q41668626 | ||
| Signal transduction by wild-type and leukemogenic Abl proteins. | Q41679375 | ||
| Protein tyrosine kinases and cancer | Q41679383 | ||
| Blockade of the Bcr-Abl kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of Bcl-xL | Q42139163 | ||
| Aberrant ALK tyrosine kinase signaling. Different cellular lineages, common oncogenic mechanisms | Q42857007 | ||
| BCR-ABL down-regulates the DNA repair protein DNA-PKcs | Q43551023 | ||
| Expression of the oncogenic NPM-ALK chimeric protein in human lymphoid T-cells inhibits drug-induced, but not Fas-induced apoptosis. | Q43796925 | ||
| Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. | Q46246951 | ||
| Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma | Q48075493 | ||
| Expression of a distinctive BCR-ABL oncogene in Ph1-positive acute lymphocytic leukemia (ALL). | Q48329182 | ||
| v-src induces cisplatin resistance by increasing the repair of cisplatin-DNA interstrand cross-links in human gallbladder adenocarcinoma cells. | Q54104153 | ||
| BCR-ABL-mediated inhibition of apoptosis with delay of G2/M transition after DNA damage: a mechanism of resistance to multiple anticancer agents. | Q54166756 | ||
| Primary chromosomal rearrangements of leukemia are frequently accompanied by extensive submicroscopic deletions and may lead to altered prognosis | Q57791069 | ||
| E1A overcomes the apoptosis block in BCR-ABL+ leukemia cells and renders cells susceptible to induction of apoptosis by chemotherapeutic agents | Q64380573 | ||
| Multiple pathways of recombination define cellular responses to cisplatin | Q64388676 | ||
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | drug resistance | Q12147416 |
| apoptotic process | Q14599311 | ||
| P304 | page(s) | 4189-4201 | |
| P577 | publication date | 2002-06-01 | |
| P1433 | published in | Molecular and Cellular Biology | Q3319478 |
| P1476 | title | Fusion tyrosine kinases induce drug resistance by stimulation of homology-dependent recombination repair, prolongation of G(2)/M phase, and protection from apoptosis | |
| P478 | volume | 22 |
| Q53043418 | A Phase I Study of Topotecan, Carboplatin and the PARP Inhibitor Veliparib in Acute Leukemias, Aggressive Myeloproliferative Neoplasms, and Chronic Myelomonocytic Leukemia. |
| Q49951210 | A matter of life and death: stem cell survival in tissue regeneration and tumour formation |
| Q40424263 | Activation and inhibition of anaplastic lymphoma kinase receptor tyrosine kinase by monoclonal antibodies and absence of agonist activity of pleiotrophin. |
| Q34103307 | Adenoviral vector driven by a minimal Rad51 promoter is selective for p53-deficient tumor cells |
| Q44746331 | An oncogenic tyrosine kinase inhibits DNA repair and DNA-damage-induced Bcl-xL deamidation in T cell transformation |
| Q36158713 | Anaplastic lymphoma kinase and its signalling molecules as novel targets in lymphoma therapy. |
| Q33727572 | BCR-ABL stimulates mutagenic homologous DNA double-strand break repair via the DNA-end-processing factor CtIP. |
| Q30537656 | BCR-ABL1 kinase inhibits uracil DNA glycosylase UNG2 to enhance oxidative DNA damage and stimulate genomic instability. |
| Q50614050 | BCR-ABL1-positive CML and BCR-ABL1-negative chronic myeloproliferative disorders: some common and contrasting features. |
| Q37743173 | BCR-ABL: a multi-faceted promoter of DNA mutation in chronic myelogeneous leukemia |
| Q36865331 | BCR/ABL and other kinases from chronic myeloproliferative disorders stimulate single-strand annealing, an unfaithful DNA double-strand break repair |
| Q39810024 | BCR/ABL downregulates DNA-PK(CS)-dependent and upregulates backup non-homologous end joining in leukemic cells. |
| Q33796384 | BCR/ABL modifies the kinetics and fidelity of DNA double-strand breaks repair in hematopoietic cells |
| Q35022527 | BCR/ABL regulates response to DNA damage: the role in resistance to genotoxic treatment and in genomic instability |
| Q39625105 | BCR/ABL stimulates WRN to promote survival and genomic instability. |
| Q37836926 | Chronic myeloid leukemia cells refractory/resistant to tyrosine kinase inhibitors are genetically unstable and may cause relapse and malignant progression to the terminal disease state |
| Q36978266 | Clinical relevance of the homologous recombination machinery in cancer therapy |
| Q92881254 | Clinicopathological and Prognostic Characteristics of RAD51 in Colorectal Cancer |
| Q40609712 | Critical role of STAT5 activation in transformation mediated by ZNF198-FGFR1. |
| Q26778614 | Cross talk of tyrosine kinases with the DNA damage signaling pathways |
| Q35205030 | Crosstalk between translesion synthesis, Fanconi anemia network, and homologous recombination repair pathways in interstrand DNA crosslink repair and development of chemoresistance |
| Q34780162 | Cytostatic and cytotoxic effects of tyrphostin AG1296 on RMS cells |
| Q36324767 | DNA Repair--A Double-Edged Sword in the Genomic Stability of Cancer Cells--The Case of Chronic Myeloid Leukemia. |
| Q39942882 | DNA damage and homologous recombination signaling induced by thymidylate deprivation |
| Q38106985 | DNA double-strand break repair as determinant of cellular radiosensitivity to killing and target in radiation therapy |
| Q38097536 | DNA repair and cytotoxic drugs: the potential role of RAD51 in clinical outcome of non-small-cell lung cancer patients. |
| Q37229934 | DNA repair by homologous recombination, but not by nonhomologous end joining, is elevated in breast cancer cells. |
| Q37662338 | Direct interaction of Ikaros and Foxp1 modulates expression of the G protein-coupled receptor G2A in B-lymphocytes and acute lymphoblastic leukemia. |
| Q39653651 | Down-Regulation of Rad51 Expression Overcomes Drug Resistance to Gemcitabine in Human Non–Small-Cell Lung Cancer Cells |
| Q40038637 | Efficiency of olaparib in colorectal cancer patients with an alteration of the homologous repair protein |
| Q39841334 | Emodin enhances gefitinib-induced cytotoxicity via Rad51 downregulation and ERK1/2 inactivation |
| Q24670609 | Enhanced phosphorylation of Nbs1, a member of DNA repair/checkpoint complex Mre11-RAD50-Nbs1, can be targeted to increase the efficacy of imatinib mesylate against BCR/ABL-positive leukemia cells |
| Q40675131 | Free radical scavengers can differentially modulate the genotoxicity of amsacrine in normal and cancer cells |
| Q33591867 | Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia |
| Q40676163 | Fusion oncogenic tyrosine kinases alter DNA damage and repair after genotoxic treatment: role in drug resistance? |
| Q36398134 | Fusion tyrosine kinase mediated signalling pathways in the transformation of haematopoietic cells. |
| Q36512142 | Fusion tyrosine kinases: a result and cause of genomic instability |
| Q37789009 | Genetic instability in inherited and sporadic leukemias. |
| Q46406409 | Genomic instability is a principle pathologic feature of FLT3 ITD kinase activity in acute myeloid leukemia leading to clonal evolution and disease progression |
| Q37738460 | Genomic instability: The cause and effect of BCR/ABL tyrosine kinase |
| Q28611377 | Homologous recombination and cell cycle checkpoints: Rad51 in tumour progression and therapy resistance |
| Q38143961 | How should we define STAT3 as an oncogene and as a potential target for therapy? |
| Q39612979 | Imatinib increases cytotoxicity of melphalan and their combination allows an efficient killing of chronic myeloid leukemia cells. |
| Q44719681 | Imatinib sensitizes CLL lymphocytes to chlorambucil |
| Q46547397 | Involvement of Rad51 in cytotoxicity induced by epidermal growth factor receptor inhibitor (gefitinib, IressaR) and chemotherapeutic agents in human lung cancer cells. |
| Q24318979 | JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin |
| Q37070370 | Jak2/Stat5 signaling in mammogenesis, breast cancer initiation and progression |
| Q26991810 | Janus kinase deregulation in leukemia and lymphoma |
| Q37148115 | Loss of the xeroderma pigmentosum group B protein binding site impairs p210 BCR/ABL1 leukemogenic activity |
| Q39088028 | Lung cancer tumorigenicity and drug resistance are maintained through ALDH(hi)CD44(hi) tumor initiating cells |
| Q39017730 | Modulation of apoptosis-related cell signalling pathways by curcumin as a strategy to inhibit tumor progression |
| Q40138545 | Multipotent hematopoietic cells susceptible to alternative double-strand break repair pathways that promote genome rearrangements |
| Q41817207 | Non-homologous DNA end joining in normal and cancer cells and its dependence on break structures. |
| Q38177820 | Oxidative metabolism in cancer: A STAT affair? |
| Q30160146 | Phosphatidylinositol 3-kinase p85{alpha} subunit-dependent interaction with BCR/ABL-related fusion tyrosine kinases: molecular mechanisms and biological consequences |
| Q41217822 | Poly (ADP-Ribose) Polymerase Inhibitor Hypersensitivity in Aggressive Myeloproliferative Neoplasms |
| Q36261964 | Polymorphism within the distal RAD51 gene promoter is associated with colorectal cancer in a Polish population |
| Q38139571 | Potential mechanisms of disease progression and management of advanced-phase chronic myeloid leukemia |
| Q39536492 | RAD51 overexpression is a negative prognostic marker for colorectal adenocarcinoma |
| Q38744610 | RAD51B as a potential biomarker for early detection and poor prognostic evaluation contributes to tumorigenesis of gastric cancer |
| Q35872003 | Reactive Oxygen Species and Mitochondrial DNA Damage and Repair in BCR-ABL1 Cells Resistant to Imatinib |
| Q33952859 | Regulation of Rad51 promoter |
| Q35113329 | Role of homologous recombination in carcinogenesis. |
| Q27023204 | Targeting DNA damage response in cancer therapy |
| Q37960389 | Targeting DNA repair and the cell cycle in glioblastoma |
| Q30010486 | Targeting RAD51 phosphotyrosine-315 to prevent unfaithful recombination repair in BCR-ABL1 leukemia |
| Q56355417 | Targeting WEE1 to enhance conventional therapies for acute lymphoblastic leukemia |
| Q34277769 | Targeting abnormal DNA double-strand break repair in tyrosine kinase inhibitor-resistant chronic myeloid leukemias |
| Q38184667 | Targeting homologous recombination-mediated DNA repair in cancer |
| Q54186992 | The RAD51 135G>C polymorphism is related to the effect of adjuvant therapy in early breast cancer. |
| Q39697762 | The cdk5 kinase regulates the STAT3 transcription factor to prevent DNA damage upon topoisomerase I inhibition. |
| Q28266986 | The consequences of Rad51 overexpression for normal and tumor cells |
| Q39249477 | The modulatory effect of melatonin on genotoxicity of irinotecan in healthy human lymphocytes and cancer cells. |
| Q37802462 | The role of Stat5 transcription factors as tumor suppressors or oncogenes |
| Q39996855 | The role of repair protein Rad51 in synergistic cytotoxicity and mutagenicity induced by epidermal growth factor receptor inhibitor (Gefitinib, IressaR) and benzo[a]pyrene in human lung cancer. |
| Q36695924 | Tyrosine kinase inhibitor AG1024 exerts antileukaemic effects on STI571-resistant Bcr-Abl expressing cells and decreases AKT phosphorylation. |
| Q36088545 | UV Differentially Induces Oxidative Stress, DNA Damage and Apoptosis in BCR-ABL1-Positive Cells Sensitive and Resistant to Imatinib |
| Q24619366 | Up-regulation of WRN and DNA ligase IIIalpha in chronic myeloid leukemia: consequences for the repair of DNA double-strand breaks |
| Q37081622 | Use of the Rad51 promoter for targeted anti-cancer therapy |
| Q36132014 | What have we learnt from mouse models of NPM-ALK-induced lymphomagenesis? |
Search more.